Nontoxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 21, 2013, Pages 8668-8673

  Quispe Tintaya, Wilber ^a   Chandra, Dinesh ^a   Jahangir, Arthee ^a   Harris, Matthew ^a   Casadevall, Arturo ^a   Dadachova, Ekaterina ^a   Gravekamp, Claudia ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOISOTOPE; RHENIUM 188;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; IMMUNE SYSTEM; IN VIVO STUDY; LISTERIA MONOCYTOGENES; METASTASIS; MOLECULAR STABILITY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION SAFETY; RADIOACTIVITY; TUMOR MICROENVIRONMENT;

ANIMALS; CELL LINE, TUMOR; FEMALE; ISOTOPE LABELING; LISTERIA; MICE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; RADIOISOTOPES; RHENIUM;

EID: 84878123970     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1211287110     Document Type: Article

References (25)

1. Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3: 157-188.
2. Moore MJ, et al.; National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15): 1960-1966.
3. Kulke MH, et al. (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25(30): 4787-4792.
4. Kim SH, Castro F, Paterson Y, Gravekamp C (2009) High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res 69(14): 5860-5866.
5. Benhardt P, Speer TW (2010) Targeted Radionuclide Therapy, ed Speer T (Lippincott Williams & Wilkins, Philadelphia), pp 263-278.
6. Qu CF, et al. (2005) In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595. Cancer Biol Ther 4(8): 848-853.
7. Milenic DE, et al. (2005) Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 20(5): 557-568.
8. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH (2007) PAM4- reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 13(24): 7380-7387.
9. Sultana A, et al. (2009) Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intraarterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer 9:66.
10. Dadachova E, et al. (2004) Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci USA 101(41): 14865-14870.
11. Maciag PC, Radulovic S, Rothman J (2009) The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 27(30): 3975-3983.
12. Gravekamp C, Paterson Y (2010) Harnessing Listeria monocytogenes to target tumors. Cancer Biol Ther 9: 1-9.
13. Klein M, et al. (2013) Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer 2013:828329.
14. Portnoy DA, Auerbuch V, Glomski IJ (2002) The cell biology of Listeria monocytogenes infection: The intersection of bacterial pathogenesis and cell-mediated immunity. J Cell Biol 158(3): 409-414.
15. Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3(6): 488-499.
16. Toledo-Arana A, et al. (2009) The Listeria transcriptional landscape from saprophytism to virulence. Nature 459(7249): 950-956.
17. Rácz P, Tenner K, Mérö E (1972) Experimental Listeria enteritis. I. An electron microscopic study of the epithelial phase in experimental listeria infection. Lab Invest 26(6): 694-700.
18. Rosen H, Gordon S (1987) Monoclonal antibody to the murine type 3 complement receptor inhibits adhesion of myelomonocytic cells in vitro and inflammatory cell recruitment in vivo. J Exp Med 166(6): 1685-1701.
19. Brockstedt DG, et al. (2005) Killed but metabolically active microbes: A new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med 11(8):853-860, 10.1038/nm1276.
20. Heisig M, et al. (2011) Specific antibody-receptor interactions trigger InlAB-independent uptake of Listeria monocytogenes into tumor cell lines. BMC Microbiol 11:163.
21. Yu YA, et al. (2004) Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 22(3): 313-320.
22. Patyar S, et al. (2010) Bacteria in cancer therapy: A novel experimental strategy. J Biomed Sci 17(1):21.
23. Corbett TH, et al. (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44(2): 717-726.
24. Kim SH, et al. (2008) Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br J Cancer 99(5): 741-749.
25. Gunn GR, et al. (2001) Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167(11): 6471-6479.